Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

November 2019; 6 (6) Clinical/Scientific NotesOpen Access

Ineffective treatment of PML with pembrolizumab

Exhausted memory T-cell subsets as a clue?

Marc Pawlitzki, View ORCID ProfileTilman Schneider-Hohendorf, Leoni Rolfes, Sven G. Meuth, Heinz Wiendl, View ORCID ProfileNicholas Schwab, Oliver M. Grauer
First published October 9, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000627
Marc Pawlitzki
From the Department of Neurology with Institute of Translational Neurology, University of Muenster, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tilman Schneider-Hohendorf
From the Department of Neurology with Institute of Translational Neurology, University of Muenster, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tilman Schneider-Hohendorf
Leoni Rolfes
From the Department of Neurology with Institute of Translational Neurology, University of Muenster, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven G. Meuth
From the Department of Neurology with Institute of Translational Neurology, University of Muenster, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heinz Wiendl
From the Department of Neurology with Institute of Translational Neurology, University of Muenster, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Schwab
From the Department of Neurology with Institute of Translational Neurology, University of Muenster, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas Schwab
Oliver M. Grauer
From the Department of Neurology with Institute of Translational Neurology, University of Muenster, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Ineffective treatment of PML with pembrolizumab
Exhausted memory T-cell subsets as a clue?
Marc Pawlitzki, Tilman Schneider-Hohendorf, Leoni Rolfes, Sven G. Meuth, Heinz Wiendl, Nicholas Schwab, Oliver M. Grauer
Neurol Neuroimmunol Neuroinflamm Nov 2019, 6 (6) e627; DOI: 10.1212/NXI.0000000000000627

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
666

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Progressive multifocal leukoencephalopathy (PML) is a rare pathologic CNS condition caused by JC polyomavirus (JCPyV) in immunodeficient patients. Immune checkpoint inhibition was previously reported to potentially facilitate the antiviral response.1

Here, we present an ultimately fatal case, where a patient with PML was treated with the anti-programmed cell death protein (PD)-1 immune checkpoint inhibitor pembrolizumab and compare it with immunologic measurements of samples from a recently published reference case with favorable outcome.2

Case report

A 38-year-old Caucasian man was diagnosed with combined immunoglobulin (Ig) G and IgA deficiency and subsequently treated with IV immunoglobulins at regular intervals. In addition, he developed recurrent severe immune thrombocytopenia, responsive to high dose of methylprednisolone, azathioprine, and at last rituximab.

As Behçet disease had additionally been diagnosed, continued immunotherapy consisted of oral prednisolone 10 mg/d and recurrent application of IV or subcutaneous immunoglobulins at a 14- or 21-day interval.

In 2018, the patient developed progressive hemianopsia and left-sided hemiparesis. Multiple fluid-attenuated inversion recovery hyperintense lesions in cerebral white matter could be detected on MRI (figure e-1A, links.lww.com/NXI/A153). PCR amplification of JCPyV DNA revealed a very high copy number (2,561,955 copies/mL) in the CSF. Cellular immune status showed complete B-cell depletion (0 cell/µL) and low T-cell counts, especially in CD4+ lymphocytes (CD3+698 cells/µL, CD4+ 181/µL, CD8+ 511/µL, CD4/CD8 ratio 0.35). The patient was treated with 2 courses of pembrolizumab (2 mg/kg of body weight, 3-week interval) in addition to continued recurrent administration of IV immunoglobulins (20 g every second weeks). One week after the last administration of pembrolizumab, the patient developed a status epilepticus and required temporary intensive care unit treatment. MRI showed progression of PML (figure e-1B and C, links.lww.com/NXI/A153), without evidence of gadolinium-enhancing lesions as a possible indicator of immune reconstitution inflammatory syndrome. JCPyV DNA viral load in CSF increased to 7,685,000 copies/mL. Pembrolizumab treatment was not continued because of the poor general condition of the patient, who died 4 weeks later.

To get further insights into the pathophysiology, we retrospectively performed a detailed immunologic assessment for evaluation of potential treatment effects of pembrolizumab in our and a previously published case (reference case), who was diagnosed for PML and initially evaluated for anti-PD-1 treatment at our clinic.2

Polyclonal immune response (figure, A) and PD-1 expression of CD4+ and CD8+ memory T cells of both patients were average before pembrolizumab administration (figure, B; T1). After 2 courses of pembrolizumab (T2), PD-1 was downregulated in the presented case (figure B; T2 was not available for the reference case).1 JCPyV VP1-specific T cells at baseline were present among CD8+, but very low among CD4+ T cells in the presented case (figure, C). Further analysis showed higher amounts of progenitor-exhausted memory T cells (% T-cell factor-1+ of PD-1+CD45RA−) in the reference case2 at baseline (figure, D; T1), as well as healthy controls, and a notable increase in terminally exhausted memory T cells (% Ki-67+ of PD-1+ CD45RA−) in the fatal case after pembrolizumab administration (figure, E).3

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Immunologic assessment of pembrolizumab treatment in the presented and reference case

CD4+ and CD8+ T cells were analyzed by flow cytometry after isolation of peripheral blood mononuclear cells (healthy controls (○), n = 9, the presented patient (◆), and the reference case (▲)). Cytokine production was analyzed after 6 hours of stimulation from PBMC isolated before (T1) and after (T2) pembrolizumab administration. CD4 (A–E) and CD8 (F–J) T-cell IFN-γ expression after phorbol-12-myristate 13-acetate/ionomycin/brefeldin A (PMA, A) or JCVyV-VP1 peptide (VP1, C) stimulation is indicated. PD-1 expression of CD45RA− memory T cells (B). T-cell factor-1 expression of PD-1+ CD45RA− memory T cells (progenitor-exhausted memory T cells, D) and Ki-67 expression of PD-1+ CD45RA− memory T cells (terminally exhausted memory T cells, E) are outlined.

Discussion

Very recently, a small case series including 8 patients1 with varied underlying causes of immune compromise plus one singular case,2 all treated with pembrolizumab, was published and showed heterogeneous results. One possible reason could be the varied underlying causes of immune incompetence including oncologic, viral, and idiopathic entities. In addition, our presented fatal case of PML supports the assumption that a high viral load at diagnosis negatively correlates with PML outcome,4 independent of pembrolizumab treatment, but furthermore indicates that pembrolizumab treatment might only be favorable early on. In contrast to an earlier report, decreased PD-1 expression on T cells after pembrolizumab administration was not indicative of treatment success in the presented case,1 neither was the amount of JCPyV-specific CD8+ T cells in the compared cases.5 However, because the presented, ultimately fatal, case did not elicit a marked CD4+ T-cell response, whereas the reference case had a detectable CD4+ T-cell response to viral protein-1 peptide already before pembrolizumab administration, it is tempting to speculate that a CD4 T-cell response is also necessary to sufficiently control JCPyV.6 This is corroborated by the HIV field, where the virus-mediated depletion of CD4+ T cells can lead to PML in late stages of disease, and JCPyV-specific CD4+ T cells were shown to be critical for PML survival.7 Of interest, it was shown very recently that the amount of progenitor-exhausted memory T cells is associated with prolonged progression-free survival in patients with melanoma receiving anti-PD-1 therapy.3 Fitting to this observation, the reference case showed higher amounts of progenitor-exhausted T cells before pembrolizumab administration, whereas the fatal case presented with a phenotype of terminally exhausted T cells, in particular at T2, which were shown to be less responsive to anti-PD1 therapy.3

Unfortunately, the clinical decline did not allow treatment continuation, although major adverse events after pembrolizumab administration were not observed. Although we only describe 1 case in detail, the amount of CD4+ JCPyV-specific T cells, progenitor-exhausted memory T cells, as well as the time point of anti-PD-1 administration and JCPyV viral load could be promising indicators in future studies to evaluate the efficacy of PML treatment with pembrolizumab.

Study funding

The authors acknowledge support from the Open Access Publication Fund of the University of Muenster.

Disclosure

M. Pawlitzki received speaker honoraria from Roche, Genzyme, and Novartis and travel/accommodation/meeting expenses from Novartis, Biogen, Genzyme, and Merck Serono. T. Schneider-Hohendorf received travel support from Novartis and Biogen. L. Rolfes received travel reimbursements from Merck Serono and Sanofi Genzyme. S.G. Meuth receives honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. H. Wiendl received compensation for serving on scientific advisory boards/steering committees for Bayer Healthcare, Biogen, Sanofi Genzyme, Merck Serono, and Novartis. He has received speaker honoraria and travel support from Bayer Vital GmbH, Bayer Schering AG, Biogen, CSL Behring, EMD Serono, Fresenius Medical Care, Genzyme, Merck Serono, Omniamed, Novartis, and Sanofi Aventis. He has received compensation as a consultant from Biogen, Merck Serono, Novartis, Roche, and Sanofi Genzyme. H. Wiendl also received research support from Bayer Healthcare, Bayer Vital, Biogen, Merck Serono, Novartis, Sanofi Genzyme, Sanofi US and Teva Pharma, Merck Serono, and Novartis. N. Schwab received travel support from Novartis, Biogen, and Genzyme. O.M. Grauer received speaker honoraria and travel/meeting expenses from Roche and MagForce. He received compensation as a consultant from Bristol-Myers Squibb and Gilead Sciences and research support from Bristol-Myers Squibb. Go to Neurology.org/NN for full disclosures.

Appendix Authors

Table
Table

Footnotes

  • ↵* These authors contributed equally to this work.

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the Open Access Publication Fund WWU.

  • Editorial, page e629

  • Clinical/Scientific Notes, page e628

  • Received July 3, 2019.
  • Accepted in final form August 21, 2019.
  • Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Cortese I,
    2. Muranski P,
    3. Enose-Akahata Y, et al
    . Pembrolizumab treatment for progressive multifocal leukoencephalopathy. New Engl J Med 2019;380:1597–1605.
    OpenUrl
  2. 2.↵
    1. Rauer S,
    2. Marks R,
    3. Urbach H, et al
    . Treatment of progressive multifocal leukoencephalopathy with pembrolizumab. N Engl J Med 2019;380:1676–1677.
    OpenUrl
  3. 3.↵
    1. Miller BC,
    2. Sen DR,
    3. Al Abosy R, et al
    . Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 2019;20:326–336.
    OpenUrlCrossRef
  4. 4.↵
    1. Blankenbach K,
    2. Schwab N,
    3. Hofner B,
    4. Adams O,
    5. Keller-Stanislawski B,
    6. Warnke C
    . Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology 2019;92:e2232–e2239.
    OpenUrl
  5. 5.↵
    1. Koralnik IJ
    . Can immune checkpoint inhibitors keep JC virus in check? N Engl J Med 2019;380:1667–1668.
    OpenUrl
  6. 6.↵
    1. Yousef S,
    2. Planas R,
    3. Chakroun K, et al
    . TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus-specific CD4+ T cells during viral infection. J Immunol 2012;189:3618–3630.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Gasnault J,
    2. Kahraman M,
    3. Goër Herve MGde,
    4. Durali D,
    5. Delfraissy JF,
    6. Taoufik Y
    . Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 2003;17:1443–1449.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Case report
    • Discussion
    • Study funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • Pembrolizumab as a treatment for PML?Waiting for Godot
  • Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency

Topics Discussed

  • Autoimmune diseases
  • Viral infections

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathy
    Evelyn Dubois, Christoph Ruschil, Felix Bischof et al.
    Neurology - Neuroimmunology Neuroinflammation, October 29, 2015
  • Articles
    Fatal PML associated with efalizumab therapy
    Insights into integrin αLβ2 in JC virus control
    N. Schwab, J.C. Ulzheimer, R.J. Fox et al.
    Neurology, February 01, 2012
  • Case
    Immune Reconstitution Syndrome After Nivolumab for Progressive Multifocal Leukoencephalopathy
    Julien Haroche, Fleur Cohen Aubart, Karima Mokhtari et al.
    Neurology: Clinical Practice, February 03, 2020
  • Views & Reviews
    Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients
    A. Venkataramana, C. A. Pardo, J. C. McArthur et al.
    Neurology, August 07, 2006
Neurology - Neuroimmunology Neuroinflammation: 10 (3)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise